Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

Research output: Contribution to journalReview article

102 Citations (Scopus)
197 Downloads (Pure)

Abstract

The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases. These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal. Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them. In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled. In addition, we consider the important challenges to drug discovery strategies and the new technologies that can address them. The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.

Original languageEnglish
Pages (from-to)217-231
Number of pages15
JournalNature Reviews Microbiology
Volume15
Issue number4
Early online date27 Feb 2017
DOIs
Publication statusPublished - Apr 2017

Fingerprint

Drug Discovery
Public Health
Neglected Diseases
Disease Eradication
African Trypanosomiasis
Technology
Parasitic Diseases
Chagas Disease
Drug Combinations
Pharmaceutical Preparations
Population

Keywords

  • Antiparasitic agents
  • Drug development
  • Parasite biology
  • Parasitic infection

Cite this

@article{589f81f61b61447dbfa1f282958591f9,
title = "Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need",
abstract = "The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases. These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal. Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them. In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled. In addition, we consider the important challenges to drug discovery strategies and the new technologies that can address them. The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.",
keywords = "Antiparasitic agents , Drug development , Parasite biology , Parasitic infection",
author = "Field, {Mark C.} and David Horn and Fairlamb, {Alan H.} and Ferguson, {Michael A. J.} and Gray, {David W.} and Read, {Kevin D.} and {De Rycker}, Manu and Torrie, {Leah S.} and Wyatt, {Paul G.} and Susan Wyllie and Gilbert, {Ian H.}",
note = "The authors are grateful to the following funding bodies for financial support: The Wellcome Trust (strategic grants 077705, 083481, 092340, 100476 and 105021), Wellcome Trust Senior Investigator Awards to D.H., M.F. and M.A.J.F. (grants 100320/Z/12/Z, 204697/Z/16/Z and 101842/Z/13/Z) and a Wellcome Trust Principal Research Fellowship to A.H.F (grant 079838); Drugs for Neglected Diseases Initiative (DNDi); and the UK Medical Research Council for grants to M.C.F. (MR/L018853/1 and MR/P009018/1), D.H. (MR/K000500/1) and to M.C.F and D.H. (MR/K008749/1).",
year = "2017",
month = "4",
doi = "10.1038/nrmicro.2016.193",
language = "English",
volume = "15",
pages = "217--231",
journal = "Nature Reviews Microbiology",
issn = "1740-1526",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Anti-trypanosomatid drug discovery

T2 - an ongoing challenge and a continuing need

AU - Field, Mark C.

AU - Horn, David

AU - Fairlamb, Alan H.

AU - Ferguson, Michael A. J.

AU - Gray, David W.

AU - Read, Kevin D.

AU - De Rycker, Manu

AU - Torrie, Leah S.

AU - Wyatt, Paul G.

AU - Wyllie, Susan

AU - Gilbert, Ian H.

N1 - The authors are grateful to the following funding bodies for financial support: The Wellcome Trust (strategic grants 077705, 083481, 092340, 100476 and 105021), Wellcome Trust Senior Investigator Awards to D.H., M.F. and M.A.J.F. (grants 100320/Z/12/Z, 204697/Z/16/Z and 101842/Z/13/Z) and a Wellcome Trust Principal Research Fellowship to A.H.F (grant 079838); Drugs for Neglected Diseases Initiative (DNDi); and the UK Medical Research Council for grants to M.C.F. (MR/L018853/1 and MR/P009018/1), D.H. (MR/K000500/1) and to M.C.F and D.H. (MR/K008749/1).

PY - 2017/4

Y1 - 2017/4

N2 - The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases. These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal. Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them. In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled. In addition, we consider the important challenges to drug discovery strategies and the new technologies that can address them. The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.

AB - The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases. These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal. Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them. In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled. In addition, we consider the important challenges to drug discovery strategies and the new technologies that can address them. The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.

KW - Antiparasitic agents

KW - Drug development

KW - Parasite biology

KW - Parasitic infection

U2 - 10.1038/nrmicro.2016.193

DO - 10.1038/nrmicro.2016.193

M3 - Review article

C2 - 28239154

VL - 15

SP - 217

EP - 231

JO - Nature Reviews Microbiology

JF - Nature Reviews Microbiology

SN - 1740-1526

IS - 4

ER -